Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cypep-1 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Cytovation
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intratumoral, Intravenous
01
Overview
CyPep-1 + pembrolizumab is a combination therapy being investigated for various advanced solid tumors. CyPep-1 is a chemically synthesized peptide with oncolytic properties that selectively targets cancer cells based on their altered molecular composition. It works by removing the surrounding cell membrane of cancer cells, which releases tumor neoantigens to the microenvironment and potentially induces an anti-tumor immune response. Pembrolizumab (KEYTRUDA) is an anti-PD-1 antibody that blocks signals that inhibit the immune system, allowing it to attack tumor cells. The combination is designed to generate an enhanced immune response against cancer cells, with CyPep-1 administered via intratumoral injection every two weeks (Q2W) and pembrolizumab following a Q6W schedule as per standard of care.
- Brand names
- Keytruda
- Other names
- getacatetide + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on cypep-1 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cypep-1 + pembrolizumab.